---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-075880"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2024-06-21T23:59:59+00:00"
generated_at: "2026-06-01T02:47:52.142989+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma FY2024 net loss $12.9M; STRIVE-ON trial on track for NDA in H1 2025

## Summary
- FY2024 net loss $12.9M ($1.35 per share), down from $42.4M in FY2023; decrease due to prior year impairments not recurring and restructuring.
- R&D expenses fell to $4.7M from $10.0M; G&A expenses down to $6.4M from $7.6M reflecting strategic realignment toward GTX-104.
- Cash and equivalents $23.0M as of March 31, 2024; projected runway into Q2 2026.
- STRIVE-ON Phase 3 safety trial enrollment on track; potential NDA submission to FDA in first half of 2025.
- Completed $7.5M private placement in September 2023; deprioritized GTX-102 and GTX-101 to focus on GTX-104.

## SEC filing metadata
- accession: 0000950170-24-075880
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2024-06-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017024075880/0000950170-24-075880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017024075880/acst-20240621.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-075880
- JSON: https://secwatch.observer/filing/0000950170-24-075880.json
- Plain text: https://secwatch.observer/filing/0000950170-24-075880.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.